ST. LOUIS--(BUSINESS WIRE)--Aug 26, 2025--
Confluence Genetics, LLC, a leading seed innovation company, today announced positive results from a comprehensive 20-week turkey feeding trial conducted in collaboration with a large poultry integrator. The study validates the commercial advantages of soybean meal made from Confluence Genetics' ProVIA™ Ultra-High Protein, Low Oligosaccharide (UHP-LO) soybeans as a complete replacement for conventional soybean meal in turkey diet formulations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826401347/en/
The large-scale trial in Iowa, involving 3,072 male turkeys, demonstrated that UHP-LO soybean meal (SBM) delivers enhanced nutritional efficiency and economic benefits for turkey producers. Birds fed diets containing UHP-LO SBM showed higher final body weights (2.5%), improved feed conversion ratio (3.9%), and increased white meat yield (5.9%), confirming the superior nutritional profile of Confluence Genetics' proprietary soybean genetics.
"This comprehensive turkey trial represents a significant milestone in validating the commercial benefits of our UHP-LO soybean meal across multiple poultry species," said Matt Begemann, Senior Director of R&D at Confluence Genetics. "The consistent performance improvements we're seeing – from broilers to turkeys – demonstrate the transformative potential of our proprietary soybean genetics. With 14% higher protein content and enhanced energy density, our UHP-LO soybean meal enables poultry producers to optimize their feed formulations, improve bird performance, and reduce costs."
The study's design incorporated a seven-phase feeding program with isocaloric and isonitrogenous diets, ensuring that performance differences could be attributed directly to the enhanced nutritional characteristics of UHP-LO SBM. The product's increased protein content and >90% reduction in anti-nutritional oligosaccharides, combined with increased metabolizable energy levels, enables more efficient nutrient utilization throughout the production cycle.
The turkey trial results build upon previous successful broiler studies, including recent collaborations with other poultry integrators that demonstrated up to 5.4% increases in broiler weights and 3.2% improvements in feed conversion ratios. These consistent findings across poultry species reinforce the broad applicability of UHP-LO soybean meal in commercial poultry production.
Beyond performance benefits, UHP-LO SBM offers turkey producers enhanced formulation flexibility. The higher protein and energy density allows nutritionists to reduce inclusion rates of soybean meal and supplemental fats while maintaining nutritional targets, delivering significant cost savings across large-scale operations.
"The turkey industry is constantly seeking ingredients that can improve both bird performance and economic returns," said Dr. Roy Brister, Ph.D., independent animal nutritionist and strategic advisor. "These trial results indicate that UHP-LO soybean meal provides turkey producers with a meaningful opportunity to optimize their operations. The combination of improved performance metrics and cost reduction potential represents a compelling value proposition for the industry."
Confluence Genetics' UHP-LO soybean meal is produced exclusively from the company's proprietary ProVIA™ soybean varieties developed through advanced plant breeding and AI-driven genetic selection. The positive turkey trial outcomes support Confluence Genetics' continued expansion in the animal feed sector, with plans to broaden the ProVIA™ soybean portfolio over the next two years to more than 30 varieties. Confluence Genetics plans to launch new herbicide tolerant ProVIA™ varieties in 2027 and 2028. The company continues to collaborate with value chain partners to ensure availability and adoption of UHP-LO SBM while further researching applications across poultry, swine, dairy, and other livestock sectors.
For more information on Confluence Genetics soybean varieties and partnership programs, visit confluence.ag.
About Confluence Genetics
Confluence Genetics is a seed innovation company where the forces of nature and technology converge—unlocking the genetic diversity of soy quality traits through proprietary genetics, its AI-driven CropOS® platform, and its Crop Accelerator. Confluence Genetics collaborates with strategic partners throughout the agribusiness value chain to meet the demand for better feed, food, and fuel. For more information, visit confluence.ag.
Cautionary Note Regarding Forward-Looking Statements Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, among other things; the Company’s current expectations and assumptions regarding the industries and markets in which it operates; potential strategic partnership and licensing opportunities; the anticipated advantages, potential and capabilities of the Company’s seed portfolio and innovation pipeline and the expected timeline for the commercialization of the Company’s current and anticipated innovations; anticipated demand for quality soy traits and the Company’s seed innovations; the expected timeline for the expansion of the Company’s seed portfolio; current projections and assumptions regarding the Company’s business and the industries and markets in which the Company currently operates or plans to operate; the Company’s strategies, outlook, positioning, resources, capabilities, and expectations for future performance or plans for growth; estimates and forecasts of financial and other performance metrics; the Company’s outlook. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: risks associated with the Company’s ability to generally execute on its business strategy; risks relating to maintaining relationships with customers and suppliers; risks associated with the effects of global and regional economic, agricultural, financial and commodities markets, political, social and health conditions. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. There may be additional risks about which the Company is presently unaware, or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any duty to update these forward-looking statements, except as otherwise required by law.
Confluence Genetics' Ultra-High Protein Low Oligosaccharide soybean variety with high-yield potential during the 2025 Growing Season.
